A new frontier in fertility innovation begins as OTO unveils Cira™, its next-generation wrist-worn biosensor, delivering personalized reproductive clarity.
OTO Fertility, a digital health platform developed by OTO Coach, is redefining reproductive care with patented biometric and AI-powered technology designed to bring clarity, precision, and confidence to fertility treatment. At the Consumer Electronic Show (CES) 2026 in Las Vegas, OTO has debuted Cira™, its newest wrist-worn fertility biosensor, marking a major advancement in how patients and clinics understand and support reproductive readiness.
Built to support every path to parenthood, from natural conception to IVF and IUI, the OTO Fertility solution combines real-time physiological data with precise guidance that help patients and fertility care teams make better-informed decisions at the moments that matter most.
OTO’s technology is rooted in more than 40 years of bioscience and space medicine, originally developed by NASA for astronauts and later refined for elite human performance. With the launch of Cira, this level of physiological precision is now delivered through a comfortable, wristband paired with OTO’s FDA-approved app. Together, they monitor more than fifty biometric markers in just minutes, including heart rate variability, nervous system regulation, and stress response, translating complex biology into a clear, actionable OTO Fertility Index™.
This index identifies when the body is in an optimized “Fertility Zone,” offering insight that goes beyond traditional fertility measures such as age, BMI, or AMH. For the first time, women can clearly see when their body is truly ready to conceive, restoring autonomy, confidence, and control in a process that has historically been defined by uncertainty.
“Until now, fertility care has existed without visibility into the most fundamental factor: how the body is responding to and recovering from stress in real time,” said Caleb Evans, Founder and CEO of OTO. “With Cira and the OTO Fertility platform app, patients gain clarity and agency, while clinicians gain a critical new layer of physiological context to guide care. We don’t replace existing fertility protocols, we make them smarter, safer, and proactive.”
Globally, one in six women experiences infertility, and despite decades of innovation, fertility treatment success rates have plateaued. In fertility care, time is the one resource that cannot be replaced. Every cycle, every intervention, and every decision carries emotional, physical, and financial weight. OTO Fertility is the first platform built to help reduce avoidable loss, poorly timed interventions, and the risk of proceeding without understanding whether the body is truly prepared, bringing a new standard of care to reproductive medicine.
The Cira wristband, OTO Fertility platform, and OTO Life app will be showcased at CES 2026 in Las Vegas in booth #53432U at the Venetian, with availability expanding across North America through partner fertility clinics and clinical programs currently underway.
For more information, visit www.otofertility.com.
For more information, visit www.otofertility.com.
